Founded in 1987 by the current CEO, Andrew Shepherd, Omega Diagnostics Group PLC is focused on selling a wide range of specialist products, primarily in the In Vitro Diagnostics (IVD), immunoassay market within three segments: Allergy and Autoimmune, Food Intolerance and Infectious Disease.
With its global headquarters based in Scotland, the Group has subsidiaries in Littleport (Cambridge, UK), Devon (UK), Reinbek (Germany), Pune
(India) and Mumbai (India). It has three manufacturing sites in the UK,one in Germany, and one in India, each site possessing ISO 9001 and ISO
13485 accreditation and being compliant with directive 98/79/EC, on IVD Medical Devices.
The Group’s diagnostic kits and systems are used in hospitals, blood banks, clinics and laboratories around the world and produce information used by physicians and practitioners to diagnose disease, make treatment decisions and monitor patients.
Originally founded as Omega Diagnostics Ltd in Scotland, the company’s global reputation stems from beginnings as a manufacturer of tests for a range of infectious diseases such as Syphilis, Tuberculosis, Dengue Fever, Chagas Disease and Malaria. The company’s export success was officially recognised with the Queen’s Award for Export Achievement in 1993, providing a solid foundation for future success.
The product range was extended following the acquisition of Genesis Diagnostics Ltd and Cambridge Nutritional Sciences Ltd in September2007 providing our customers with access to tests for the fast growing area of food intolerance testing, as well as those for autoimmune diseases – including anaemia,
connective tissue disease and renal disease.
In 2010, the Group acquired the IVD division of allergy and specific immunotherapy specialist Allergopharma Joachim Ganzer KG, giving access to a range of allergy tests for over 600 allergens.
To expand the Group’s worldwide presence and reach, in 2011 a new subsidiary, Omega Dx (Asia) Pvt Ltd, was formed in Mumbai, India.
In 2012, a new ground-breaking point-of-care test for the determination of CD4 counts in whole blood was developed by the Burnet Institute in Melbourne, Australia and licenced to Omega Diagnostics Limited.
More recently, in 2015, the Group established a new RDT manufacturing facility in Pune, India.
Today, Omega Diagnostics Group PLC is one of the UK’s leading companies in the fast growing area of immunoassay and has a global presence in over 100 countries worldwide through directly controlled subsidiaries and a strong distribution network.